Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3494245 in Healthy Participants
NCT04504435Phase 1Terminated
- Sponsor
- GSK
- Start
- Sep 2020
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3494245 in leishmaniasis (20 cohorts), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events, Number of Participants With Serious Adverse Events and 8 more. Started Sep 2020; status: terminated.
02
Drugs
GSK3494245
03
Conditions
leishmaniasis
Beyond the preview
Go deeper on NCT04504435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504435.